- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07577388
Bed Rest With a Short Cervix on Preterm Birth (BEWISE)
BEWISE - Bed Rest With a Short Cervix on Preterm Birth
Maternal AR has long been used to prevent PTB. However, definitions of AR vary widely, ranging from complete bed rest to partial limitation of physical activity for one or more hours daily.
The use of maternal AR to prevent preterm birth is largely based on observational evidence linking strenuous physical activity to an increased risk of preterm birth, and the assumption that reduced activity may decrease myometrial activity. However, the existing evidence on the clinical effects of AR remains limited and has not demonstrated a reduction in preterm birth or a delay in deliv-ery. In contrast, some studies suggest a potential increase in preterm birth following AR and instead significant adverse maternal and fetal effects.
The overall aim of this study is to compare gestational age at birth in women with a short cervix who are prescribed AR compared with women with a short cervix who are not prescribed AR (NAR).
The primary hypothesis is that NAR is non-inferior to AR in prolonging pregnancy in women with a short cervix.
Secondary hypotheses are that, compared with AR, NAR is associated with higher level of physical activity, lower risk of maternal depression, and reduced risk of loss of maternal bone mineral density.
Through the BEWISE study, we wish to implement a change in the Danish national clinical practice regarding AR from recommending AR in risk groups (current practice) to no longer recommending AR as part as routine care (new practice). We will evaluate this change in clinical practice by prospectively collecting data from women both before and after implementation of the new recommendation. The transition from AR to NAR will be implemented sequentially in each Danish region using a randomised stepped-wedge (SW) cluster design, with each region constituting a cluster. The order in which regions transition is determined by randomisation. Each region will adopt the new recommendation at 3-month intervals, resulting in full national transition from AR to NAR within 12 months Eligible participants are pregnant women in gestational age 20+0 to 33+6 and cervical length < 25 mm in singleton pregnancies and < 30 mm in multiple pregnancies. Participants must be above 18 years of age and be able to read and understand Danish or English. There are no exclusion criteria.
The primary outcome is gestational age in days (continuous).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Kirsten Bünemann, Medical Doctor, PhD-student
- Numero di telefono: +45 40329849
- Email: kirsten.bunemann@clin.au.dk
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Pregnant women with gestational age 20+0 to 33+6
- Cervical length < 25 mm in singleton pregnancies and < 30 mm in multiple pregnancies
- Above 18 years of age
- Reads and understands Danish or English
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Activity Restriction
The comparison arm reflects current Danish clinical practice in each participating region.
According to national recommendations, AR is indicated before GA 28+0, with the level of restriction determined by cervical length and clinical context.
In singleton pregnancies with a cervix <10 mm in singleton/<15 mm in twins, strict AR is prescribed, defined as bed rest with only toilet allowance.
In addition, thrombosis prophylaxis (Low Molecular Weight Heparin and compression stockings) is initiated in cases of strict AR.
In women with a cervix of 10-14 mm in singletons/15-20 mm in twins, or in cases of PPROM with a cervix <25 mm, moderate AR is prescribed, defined as 2-8 hours of daily bed rest.
The regimen is continued until 28 weeks of gestation.
|
Recommendation to restrict physical activity in pregnant women with a short cervix.
This may include increased rest or bed rest according to local clinical practice.
Altri nomi:
|
|
Sperimentale: No Activity Restriction
The intervention consists of a recommendation of NAR during pregnancy. No general or graded restrictions on daily activities are advised, and cervical length is not an indication for activity limitation, in line with current evidence. The NAR recommendation is supported by a pragmatic clinical guidance. Women are advised to avoid activities that provoke pain, increase uterine contractions, or worsen pelvic pressure. Decisions regarding hospital admission or sick leave are based on individual clinical assessment rather than cervical length. Specific advice may be provided when clinically indicated. Women are generally advised to avoid heavy weight-bearing exercise and lifting of objects exceeding approximately 10 kg. Otherwise, no specific restrictions on physical activity are imposed, provided that activities do not provoke symptoms such as pain, increased uterine contractions, or pelvic pressure. Sexual activity may be ad-dressed on an individual basis following clinical assessment. |
Recommendation to continue normal daily activity in pregnant women with a short cervix, without restricting physical activity.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Gestational age at birth
Lasso di tempo: At birth (from inclusion until delivery)
|
Gestational age at birth measured in completed days of pregnancy.
This is calculated based on the estimated due date from ultrasound (crown-rump lenght <14weeks).
|
At birth (from inclusion until delivery)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Birth before 37 weeks of gestation
Lasso di tempo: At birth
|
At birth
|
|
|
Gestational age at birth, pooled
Lasso di tempo: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Latency from inclusion to birth (days)
Lasso di tempo: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Onset of birth
Lasso di tempo: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Mode of birth
Lasso di tempo: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
- Non-occipital presentation
Lasso di tempo: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Interventions during birth
Lasso di tempo: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Degree of birth tear
Lasso di tempo: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Maternal serious morbidity
Lasso di tempo: From inclusion to 42 days after delivery
|
Admission to an intensive care unit or a unit providing 24-hour medical supervision, mechanical ventilation, or continuous vasoactive drug support at any time during pregnancy and postpartum due to pregnancy- or childbirth-related complications
|
From inclusion to 42 days after delivery
|
|
Umbilical cord arterial pH
Lasso di tempo: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
EPDS depression score
Lasso di tempo: From inclusion to 8 weeks after due date
|
From inclusion to 8 weeks after due date
|
|
|
Bone turnover marker level
Lasso di tempo: At inclusion and after 4 and 8 weeks.
|
|
At inclusion and after 4 and 8 weeks.
|
|
Lumbar spine Z-score
Lasso di tempo: 12 months after stopped breastfeeding
|
12 months after stopped breastfeeding
|
|
|
Data from SENS activity tracker
Lasso di tempo: At birth (from inclusion until delivery)
|
Step count Time in supine position
|
At birth (from inclusion until delivery)
|
|
Neonatal mortality
Lasso di tempo: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Fetal loss
Lasso di tempo: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Birth weight
Lasso di tempo: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Neonatal admission, days
Lasso di tempo: From inclusion until discharge or 44 postmenstrual weeks
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
|
CNS morbidity
Lasso di tempo: From inclusion until discharge or 44 postmenstrual weeks
|
Intraventricular haemorrhage grade III or IV, Periventricular leukomalacia
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
Gastrointestinal morbidity
Lasso di tempo: From inclusion until discharge or 44 postmenstrual weeks
|
Necrotizing enterocolitis (NEC) requiring surgery (Bell's stage 3), Spontaneous intestinal perfo-ration (SIP) requiring surgical treatment
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
Respiratory support
Lasso di tempo: From inclusion until discharge or 44 postmenstrual weeks
|
Mechanical ventilation or non-invasive ventilation (NIV)
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
Respiratory distress syndrome (RDS)
Lasso di tempo: From inclusion until discharge or 44 postmenstrual weeks
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
|
Early onset infection
Lasso di tempo: From inclusion to 5 days after birth
|
Definition: >5 days of i.v.
antibiotics where the treatment starts within the first week after delivery.
|
From inclusion to 5 days after birth
|
|
Apgar score at 5 minutes
Lasso di tempo: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Julie Glavind, Senior Consultant, MD, PhD, Aarhus Univeristy Hospital, Department of Obstetrics and Gynecology
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Disordini mentali
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Complicanze ostetriche del lavoro
- Malattie uterine
- Malattie genitali, femmina
- Disturbi dell'umore
- Malattie della cervice uterina
- Disturbi puerperali
- Disordine depressivo
- Aborto, Abituale
- Aborto spontaneo
- Comportamento
- Nascita prematura
- Complicazioni della gravidanza
- Depressione, dopo il parto
- Travaglio ostetrico, prematuro
- Incompetenza cervicale uterina
- Attività motoria
- Attività motoria
- Movimento
- Fenomeni fisiologici muscoloscheletrici
- Fenomeni fisiologici muscoloscheletrici e neurali
- Terapie
- Esercizio
- Riposo a letto
Altri numeri di identificazione dello studio
- 16-0500-15
- 4308-00216B (Altro numero di sovvenzione/finanziamento: Independent Research Fund Denmark)
- 1-10-72-96-25 (Altro identificatore: De Videnskabsetiske Komitéer For Region Midtjylland)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Activity Restriction
-
University Hospital, ToulouseAttivo, non reclutante
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); University of Rochester; University of Massachusetts...CompletatoCancro al seno | Sopravvissuto al cancro al seno | Tracker per il fitnessStati Uniti
-
Maastricht University Medical CenterSt. Antonius Hospital; Gelderse Vallei Hospital; ild care foundationCompletatoFatica | Sarcoidosi
-
prof dr Pieter GillardUniversity Colleges Leuven LimburgCompletato
-
University of the Balearic IslandsCompletatoPressione sanguigna | Allenamento di resistenzaSpagna
-
Stony Brook UniversityAttivo, non reclutanteAttività fisicaStati Uniti
-
Istituto Auxologico ItalianoReclutamentoComportamento sanitarioItalia
-
Pacific UniversityCompletato
-
University Ramon LlullCompletatoAttività fisica | Qualità della dieta | Calcio | PersonaleSpagna
-
Norwegian University of Science and TechnologyCompletatoMalattia cardiovascolare | ObesitàNorvegia